Zacks Small Cap Research – DYAI: Looking Toward Product Revenues – Go Health Pro

Zacks Small Cap Research – DYAI: Looking Toward Product Revenues – Go Health Pro

By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) enters 2025 on the cusp of generating product revenues from its relationship with Proliant. Initially, commercialization efforts and sales will be focused on recombinant serum albumin. Further down the road, additional proteins may be added including bovine albumin, bovine transferrin … Read more

Zacks Small Cap Research – QSG: F1Q25 Earnings Review: EPS Miss on Lower Revenues; Silver Transition Gaining Momentum – Go Health Pro

By Michael Kim NASDAQ:QSG READ THE FULL QSG RESEARCH REPORT Pre-market open on 11/27/24, QuantaSing (NASDAQ:QSG) reported F1Q25 (Sep) earnings results. On a GAAP basis, QSG reported net income of $11.5 million for F1Q25, or $0.21 per ADS. That said, excluding share-based compensation expenses, adjusted EPS came in at $0.23, or below our estimate of … Read more

x